Cytomegalovirus and tumor stress surveillance by binding of a human γδ T cell antigen receptor to endothelial protein C receptor

被引:234
作者
Willcox, Carrie R. [2 ]
Pitard, Vincent [1 ,3 ]
Netzer, Sonia [1 ,3 ]
Couzi, Lionel [1 ,3 ,4 ]
Salim, Mahboob [2 ]
Silberzahn, Tobias [5 ,6 ]
Moreau, Jean-Francois [1 ,3 ,7 ]
Hayday, Adrian C. [5 ,6 ]
Willcox, Benjamin E. [2 ]
Dechanet-Merville, Julie [1 ,3 ]
机构
[1] Univ Bordeaux, Unite Mixte Rech 5164, Bordeaux, France
[2] Univ Birmingham, Sch Canc Sci, Birmingham Canc Res UK Canc Ctr, Birmingham, W Midlands, England
[3] CNRS, Unite Mixte Rech 5164, Bordeaux, France
[4] CHU Bordeaux, Renal Transplantat Dept, Bordeaux, France
[5] Kings Coll London, Sch Med, Guys Hosp, Peter Gorer Dept Immunobiol, London, England
[6] Canc Res UK, London Res Inst, London, England
[7] CHU Bordeaux, Dept Immunol, Bordeaux, France
基金
英国惠康基金;
关键词
INFECTED CELLS; RECOGNITION; CANCER; EXPRESSION; COMPLEX; TRANSPLANTATION; IMMUNOTHERAPY; EXPANSION; RESPONSES;
D O I
10.1038/ni.2394
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
T cells bearing gamma delta T cell antigen receptors (TCRs) function in lymphoid stress surveillance. However, the contribution of gamma delta TCRs to such responses is unclear. Here we found that the TCR of a human V(gamma)4V(delta)5 clone directly bound endothelial protein C receptor (EPCR), which allowed gamma delta T cells to recognize both endothelial cells targeted by cytomegalovirus and epithelial tumors. EPCR is a major histocompatibility complex-like molecule that binds lipids analogously to the antigen-presenting molecule CD1d. However, the V(gamma)4V(delta)5 TCR bound EPCR independently of lipids, in an antibody-like way. Moreover, the recognition of target cells by gamma delta T cells required a multimolecular stress signature composed of EPCR and costimulatory ligand(s). Our results demonstrate how a gamma delta TCR mediates recognition of broadly stressed human cells by engaging a stress-regulated self antigen.
引用
收藏
页码:872 / 879
页数:8
相关论文
共 50 条
  • [41] Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma
    Ma, Kun
    Hu, Ping
    CANCERS, 2023, 15 (23)
  • [42] Biomarkers in chimeric antigen receptor T-cell therapy
    Kong, Weimin
    Lacey, Simon F.
    Melenhorst, Jan Joseph
    Fraietta, Joseph A.
    BIOMARKERS IN MEDICINE, 2018, 12 (05) : 415 - 418
  • [43] Chimeric antigen receptor T cell treatment in hematologic malignancies
    Goker, Hakan
    Malkan, Umit Yavuz
    Demiroglu, Haluk
    Buyukasik, Yahya
    TRANSFUSION AND APHERESIS SCIENCE, 2016, 54 (01) : 35 - 40
  • [44] Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma
    Feldman, Lisa
    Brown, Christine
    Badie, Behnam
    NEUROMOLECULAR MEDICINE, 2022, 24 (01) : 35 - 40
  • [45] State of the art and perspectives of chimeric antigen receptor T cells cell therapy for neuroblastoma
    Lutskovich, Dzmitry
    Meleshko, Alexander
    Katsin, Mikalai
    CYTOTHERAPY, 2024, 26 (10) : 1122 - 1131
  • [46] Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors
    Hong, Mihe
    Talluri, Sohan
    Chen, Yvonne Y.
    CURRENT OPINION IN BIOTECHNOLOGY, 2023, 84
  • [47] Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)
    Klampatsa, Astero
    Haas, Andrew R.
    Moon, Edmund K.
    Albelda, Steven M.
    CANCERS, 2017, 9 (09):
  • [48] Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future
    Srour, Samer A.
    Akin, Serkan
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2023, 6 (01) : 19 - 30
  • [49] Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas
    Muhsen, Ibrahim N.
    Hill, LaQuisa C.
    Ramos, Carlos A.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (06) : 1107 - 1124
  • [50] Acute T-cell lymphoblastic leukemia: chimeric antigen receptor technology may offer a new hope
    Jing, Jiajie
    Ma, Yuan
    Xie, Ziwen
    Wang, Bingyan
    Chen, Yueming
    Chi, Enjie
    Wang, Jiadong
    Zhang, Kejin
    Wang, Zhujun
    Li, Sisi
    FRONTIERS IN IMMUNOLOGY, 2024, 15